Abstract 29
To characterize the risk of cosmetic ingredients when threshold toxicity is assumed, often the 30 "margin of safety" (MoS) is calculated. This uncertainty factor is based on the systemic no observable 31 (adverse) effect level (NO(A)EL) which can be derived from in vivo repeated dose toxicity studies. As 32 in vivo studies for the purpose of the cosmetic legislation are no longer allowed in Europe and a 33 validated in vitro alternative is not yet available, it is no longer possible to derive a NO(A)EL value for 34 a new cosmetic ingredient. Alternatively, cosmetic ingredients with a low dermal bioavailability 35 might not need repeated dose data, as internal exposure will be minimal and systemic toxicity might 36 not be an issue. This study shows the possibility of identifying compounds suspected to have a low 37 dermal bioavailability based on their physicochemical properties (molecular weight, melting point, 38
topological polar surface area and log P) and their in vitro dermal absorption data. Although 39
Introduction 44
According to the European Cosmetic Regulation (EC 1223/2009), every cosmetic product on the 45 market has to be safe for human health. This safety is based on the safety of its composing 46 ingredients, their chemical structure, toxicological profile and exposure pattern. To characterize the 47 risk of a cosmetic ingredient when threshold toxicity is assumed, the calculation of a so-called 48 "margin of safety" (MoS) is applied. This uncertainty factor is used to extrapolate from test animals 49 to humans and takes into account the systemic no observable (adverse) effect level (NO(A)EL) and 50 the systemic exposure dose (SED). The former is derived either from in vivo oral repeated dose 51 toxicity studies or reproductive toxicity data. The SED is estimated by taking into account the 52 concentration (C) of the ingredient in the product, the daily amount of product exposed to per kg 53 body weight (A, derived from consumer studies) and the dermal absorption (DA) [ MoS= Organisation (WHO) an ingredient with a MoS ≥ 100 is considered to be safe (SCCS/1564/15). 56 However, with the introduction of the animal testing and marketing bans in the European cosmetic 57 legislation and due to the absence of validated in vitro replacement methods for repeated dose or 58 reproductive toxicity studies, it is no longer possible to derive a NO(A)EL to calculate the MoS for 59 newly developed cosmetic ingredients. The consequences of this legal implementation start to 60 become visible as no new UV-filters, preservatives or other cosmetic active ingredients have 61 emerged in the last 2 years. So far only substances for which in vivo repeated dose studies were 62 carried out before March 2013 have been evaluated by the SCCS. But for some particular ingredients 63 the safety assessment might not be jeopardised. Indeed, ingredients with a negligible dermal 64 bioavailability do not necessarily need repeated dose data, as internal exposure would be minimal 65 and systemic toxicity might not be a potential issue. Adding the assumption that the main route of 66 exposure to a cosmetic product is dermal and the dermal bioavailability will be in most cases even 67 lower than the oral bioavailability, it might be justifiable to base the safety assessment of such 68 compounds on local toxicity and mutagenicity/genotoxicity test results, this on the assumption that 69 no bioaccumulation is expected. In this context it is important to define when an ingredient is 70 considered to have a low bioavailability. 71
Bioavailability, defined as the fraction of the dose administered (orally, dermally or via another 72 route) that reaches the systemic circulation unchanged, is a composite parameter dependent on 73 both absorption from the site of administration and metabolism of the compound. Within the area of 74 drug discovery much research has been carried out on predicting bioavailability, particularly with 75 respect to oral administration. As absorption is a key component, simple rules have been established physicochemical properties on the prediction of oral absorption. Whilst these rules are broad, and 88 many exceptions are known, they demonstrate the principle that these simple physicochemical 89 descriptors may be useful in classifying compounds as to high or low (oral) absorption. 90
Similarly, models have been developed to predict the extent of dermal penetration based on simple 91 physicochemical properties; the most notable example being the work of Potts and Guy (1992) who 92 demonstrated a correlation between log P and MW with skin permeability. Refinements to the Potts 93 and Guy model have since been published and the inherent difficulty modelling skin permeability 94 data has been acknowledged (Steinmetz et al 2015) . One problem is that measurements of dermal 95 uptake are associated with high experimental variability, due to differences in assay conditions (e.g. 96 differences in test protocols, skin type, use of solvents/vehicles, etc) making the development of 97 robust, reliable quantitative models challenging. Another complication in modelling absorption is 98 bias within the datasets. As skin is an effective barrier, dermal absorption data tend to be highly 99 skewed towards low dermal absorption. The converse is observed for oral absorption data, as most is 100 derived from drug development where high oral absorption is desirable, consequently most 101 publically available data are for high oral absorption compounds. Despite these challenges, it would 102 clearly be beneficial if rules based on simple physicochemical descriptors could be used to identify, 103 accurately, compounds with low dermal absorption and thus low dermal bioavailability. 104
In order to investigate this possibility, a retrospective analysis of available safety evaluation data of 105 cosmetic ingredients could provide valuable information. Although the safety of cosmetic products 106 and their ingredients in Europe has to be assured by the companies' responsible person, for 107 ingredients with some concern for human health i.e. colorants, preservatives, UV-filters and hair dyes 108 provide a high quality dataset for analysis. To formulate rules to identify low bioavailability 117 compounds we undertook an empirical analysis of the cosmetic ingredients, assessed between 2000 118 and 2014 by the SCCS and its predecessors, to investigate the link between DA measured in vitro and 119 their physicochemical properties. In this study we propose a pragmatic approach that might aid in 120 assessing whether a new cosmetic ingredient is likely to have a low dermal bioavailability. 121
Method 122
When preparing the data of all compounds from the SCCS opinions for modelling, the following 123 criteria were used: 124 (i) DA measurements obtained using rat skin were excluded because of the relatively high uptake 125 when compared to human or porcine skin. 126
(ii) if more than one DA measurement per compound were available an arithmetic mean was 127 calculated. 128 (iii) descriptors were obtained for the parent form of the compounds. 129
A simplified molecular-input line-entry specification (SMILES) string for each compound was entered 130 into the Molecular Operating Environment (MOE) software (version 2011.10) and processed to 131 derive the neutralised form for the organic component. Topological polar surface area (TPSA) and 132 molecular weight (MW) were calculated using a Chemistry Development Kit (CDK) node (molecular 133 properties) available via the Konstanz Information Miner (KNIME) platform (KNIME version 2.10). The 134 octanol:water partition coefficient (log P) was calculated using KowWin® (v1.68 available within EPI 135 Suite 4.1, US EPA). Melting points (MPs) were extracted from the SCCS reports where possible. As the 136
MPs of salts differ significantly from the MP of the parent compound, data was only included if 137 available for the parent and not a salt form. This led to the creation of the data set (n = 70) used for 138 further analysis. 139
For this data set a series of rules was defined in order to classify compounds as having a high or low 140 DA. For this purpose a preliminary investigation was done using a Decision Tree Builder (KNIME 141 version 2.10), employing log P, MW, TPSA and MP to determine which descriptors performed better 142 in classifying compounds as high or low DA (data not shown here). Although the results from the 143 decision tree alone were not conclusive, they provided guidance on the key descriptors, and 144 appropriate cut-off values that could be used to distinguish between high and low DA compounds. 145
Based on these preliminary investigations, compounds were initially split into classes of low DA 146 
171
These rules can be interpreted as follows: 172
If any of the following criteria applies: (i) MW < 180 Da, (ii) log P ≥ 0.3, (iii) MP < 100°C and/or (iv) 173 TPSA < 40 Å 2 , then the compound is predicted as highly absorbed. If none of the criteria applies, the 174 compound is predicted as poorly absorbed. Table 1 summarises the results of applying this rule set to 175 the data set (n=70). 176 The rule set shows a high sensitivity of 100% for the data set (i.e. for all 23 compounds in the high DA 180 class all 23 were correctly predicted as being highly absorbed). The specificity of the rules is low as 38 181 out of 47 low DA compounds were incorrectly classified as highly absorbed rendering a specificity of 182
19.1%. 183
The results show that for the compounds studied here, when the rules predict a compound as having 184 a low DA then the compound is likely to be poorly absorbed (no false negatives were identified using 185 these rules). However, when the rules predict a compound as having a high absorption, then the 186 compound may in fact have either a high or a low DA. 187
188

Flexible analysis of the data set 189
The same rule set was again applied to the same data set, however in this case additional flexibility 190 was introduced. When a compound triggered none or only 1 of the alerts then it would still be 191 predicted as low DA. Only compounds triggering two or more alerts would be assigned to the high 192 absorption class. Table 2 shows that application of the rule set with flexible interpretation (i.e. two or more alerts 202 need to be triggered to classify the compound as high DA) leads to an increased specificity (61.7%), 203 but to a decreased sensitivity of 82.6% (i.e. 4 high DA compounds are now predicted as low DA). The 204 increase in specificity may be out-weighed by the loss of sensitivity, as greater "cost" is associated 205 with a false negative (i.e. predicting a high absorption compound as low DA). 206 207 However, it was noted that the 4 compounds that had been incorrectly classified into the low DA 208 class all had a DA of < 2%. For this reason the analysis of the data set was repeated but in this case 209 new boundaries were set for the two classes i.e. compounds for which DA was ≥ 2% were classified 210 as high DA compounds, whereas those with DA <2% were taken as low DA compounds. 211
212
Results with new boundary criteria 213
The same rule set was applied to the data set, but with the cut-off value between high and low DA 214 being set at 2%. Tables 3 and 4 show the results of applying the new cut-off value. In table 3 a 215 compound is considered to belong to the class of high DA compounds if one or more alerts are 216 triggered. In Table 4 the rule set is applied more flexibly and a compound is considered to belong to 217 the high DA class only if two or more alerts are triggered. 218 219 
227
The results given in tables 3 and 4 show that, when a cut-off value for DA of 2% is used, the 228 sensitivity of the prediction is 100% in both cases. Indeed, compounds of high DA are always 229 classified as highly absorbed; there are no false negatives. Allowing for a more flexible interpretation 230 of the rule set, i.e. that 2 or more alerts need to be triggered in order for the compound to be 231 predicted as having a high DA, increases the specificity -fewer true low DA compounds are predicted 232 as having a high DA. 233 234 In summary, using the rule set with a cut-off value of 2% will lead to high DA compounds always 235 being predicted as high (for this data set). However compounds with true low DA may be predicted 236 as either high or low. More of the true low DA compounds are correctly classified when the more 237 flexible rules are applied (specificity has increased from 15.8% to 57.9%). properties MW, MP, TPSA and log P, we have shown that rules can be extracted to identify 257 compounds suspected to have a low DA and which may be associated with a low dermal 258 bioavailability. 259
According to this study the rule set showed a sensitivity of 100% and a specificity of 20%. After 260
setting new boundary criteria and applying more flexible rules the performance of the rule set was 261 optimised. The sensitivity of the predictions remained 100%, implying that compounds with a high 262 DA are always predicted as such and the specificity was increased to 58%, without compromising the 263 sensitivity. It is indeed preferable not to identify compounds with a high DA as having a low DA. So in 264 case a compound triggers none or only one of the following alerts: MW < 180 Da, log P ≥ 0.3, MP < 265 100°C or TPSA < 40 Å 2 , it is likely to have a low DA and thus a low dermal bioavailability. The 266 presented rule set offered the best consensus between specificity and sensitivity. Adding more 267 criteria to classify a compound as high dermal absorption, did not lead to a better prediction. 268
It should be noted that this study comprises a limited set of compounds. Furthermore, several 269 difficulties were encountered in modelling these DA data. The data have been collated from the 270 results of different assays using inconsistent methodologies in terms of species, exposure times, 271 concentrations, matrices, detection methods etc. Also, it must be noted that the data set analysed 272 here is skewed very much towards low DA values and that the same rules may not apply when 273 investigating compounds from different chemical domains. Also, the possibility of bioaccumulation is 274 not taken into account in this study. Nonetheless, this pragmatic approach shows that when 275 physicochemical evidence suggests that a cosmetic ingredient has a low DA and thus low dermal 276 bioavailability, it might be worthwhile to further investigate this by performing more extensive in 277 vitro DA studies to get more reliable mean values and to confirm the very low DA (i.e. testing 278 different concentrations, using relevant excipients, increased sample size…). Although the data are 279 skewed towards low DA, in many cases the DA value used in the SCCS safety dossiers is still over-280 estimated and more extensive in vitro DA studies might enforce the reliability of the obtained results. 281
Especially when taking into account that two standard deviations are added to the mean DA value 282 when the variability between the different measurements is high or when the DA studies have not 283 been carried out under ideal test conditions. 284
285
To add further to the weight of evidence, existing computational tools could be used to predict oral 286 bioavailability (Moda et al. 2007 ; Kumar et al. 2011 ). In case oral and dermal bioavailability are both 287 low, it would strengthen the safety assessor's reasoning to omit the need to calculate the MoS, 288 making at least for this type of ingredients in vivo repeated dose toxicity studies redundant and to 289 focus on local toxicity (skin sensitisation and irritation) and mutagenicity/genotoxicity test results. 290
Since most of the existing computational tools have been developed for pharmaceuticals, evidence 291 should be provided for their applicability in the cosmetic sector. 292
293
To notice for the future is the possibility that when substantial evidence of low bioavailability is 294 provided, the internal threshold of toxicological concern (TTC) concept might be applied. This 295 probabilistic approach is used to identify human exposure thresholds below which the risk of 296 toxicological concern is low by taking into account oral/dermal absorption of the compound (internal 297 exposure) rather than external exposure (Partosch et al. 2015) . For completeness, decisions relating 298 to internal exposure following oral/dermal administration should include considerations of 299 metabolism when one wants to omit the determination of the NOA(E)L, since it will then be 300 important to consider the possibility of metabolic activation. Several in vitro and in silico models are 301 available for predicting metabolism following oral exposure and there is increasing interest in the 302 area of skin metabolism for which models are currently being developed (as reviewed recently by 303 Dumont et al 2015) . Though in the cosmetic sector the TTC concept has been accepted for the safety 304 assessment of impurities for which the identity is known but toxicity data are lacking (Kroes et al. 305 2007; SCCS/1564/15), more evidence is still needed to prove the applicability of the internal TTC for 306 cosmetic ingredients. 307 308
